Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL24052 | 0.91 | GDA (0.48) | GDAPDPK1ADORA2ADHFRCDK2 | |
| 2,6-Diaminopurine SCHEMBL29444619 | 0.91 | GDA (0.48) | GDAPDPK1ADORA2ADHFRCDK2 | |
| 2,6-Diaminopurine SCHEMBL6423146 | 0.89 | GDA (0.47) | GDAPDPK1ADORA2ADHFRCDK2 | |
| 2,6-Diaminopurine SCHEMBL8757968 | 0.89 | GDA (0.47) | GDAPDPK1ADORA2ADHFRCDK2 | |
| 2,6-Diaminopurine SCHEMBL7659157 | 0.84 | GDA (0.41) | GDAPDPK1ADORA2ACDK2DPP4 | |
| 2,6-Diaminopurine SCHEMBL1074475 | 0.84 | GDA (0.41) | GDAPDPK1ADORA2ADHFRCDK2 | |
| 2,6-Diaminopurine SCHEMBL5017251 | 0.82 | PDPK1 (0.42) | GDAPDPK1ADORA2ADHFRCDK2 | |
| SCHEMBL14678287 | 0.79 | CDK1 (0.32) | GDAPDPK1CDK2CDK1CCNB1 | |
| 2,6-Diaminopurine SCHEMBL1931238 | 0.78 | PDPK1 (0.39) | GDAPDPK1ADORA2ACDK2DPP4 | |
| Adenine SCHEMBL3619794 | 0.78 | PI4KA (0.41) | GDAADORA2APIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-07-12 | — | — | US | claimed |
| EP-2448954-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | Rutgers, The State University of New Jersey (US) | 2012-05-09 | — | — | EP | claimed |
| WO-2011003025-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-01-06 | — | — | WO | claimed |
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | ALIGOS THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4493694-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023177808-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-11466274-B2 | Modified gapmer oligonucleotides and methods of use | ALIGOS THERAPEUTICS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2448954-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | Rutgers, The State University of New Jersey (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011003025-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-01-06 | — | — | WO | disclosed |
| US-5891684-A | RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5879938-A | RIBOZYME WITH INCREASED ACTIVITY BY SUBSTITUTION OF MODIFIED NUCLEOTIDE INTO SUBSTRATE BINDING ARM OR CATALYTIC CORE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| US-5767263-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| US-5672511-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| EP-0728204-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995013378-A1 | BASE-MODIFIED ENZYMATIC NUCLEIC ACID | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368996-A1 | MODIFIED ANTISENSE OLIGONUCLEOTIDES FOR TREATING HEPATITIS B VIRUS | HAVCR2, SNRPB2, NSUN2 | GDA 684/4885PDPK1 4624/4885ADORA2A 957/4885 |
| US-20120178710-A1 | SYNTHESIS OF CYCLIC DIGUANOSINE MONOPHOSPHATE AND THIOPHOSPHATE ANALOGS THEREOF | TYMP, DTYMK, MTAP | GDA 10/4885PDPK1 1712/4885ADORA2A 491/4885 |
| US-20230383296-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | GJA1, GAP43, GJB2 | GDA 59/4885PDPK1 4042/4885ADORA2A 1617/4885 |
| US-11466274-B2 | Modified gapmer oligonucleotides and methods of use | HAVCR2, ADAR, RNMT | GDA 4/4885PDPK1 3629/4885ADORA2A 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.